Vivaldi Biosciences Announces Presentation at American Society for Virology Virtual Annual Meeting
FORT COLLINS, Colorado and VIENNA, Austria – June 15, 2020 – Vivaldi Biosciences, a clinical-stage biotechnology company developing the DeltaFLU universal influenza vaccine, today announced that Amy Aspelund, Vice President, Research & Development, is scheduled to present at the Vaccines Virtual Workshop of the 39th Annual Meeting of the American Society for Virology on June 19, 2020. Ms. Aspelund will deliver a presentation on Vivaldi’s innovative Vero cell-based vaccine manufacturing system.
The American Society for Virology’s 2020 Annual Meeting (ASV 2020), originally scheduled to take place June 13-17 in Fort Collins, CO, was cancelled due to public health concerns regarding the COVID-19 pandemic. ASV 2020 will take place in the form of Virtual Workshops.
Details of the presentation are as follows:
Presenter: Amy Aspelund, Vice President, Research & Development, Vivaldi Biosciences
Date: June 19, 2020
Time: 4:45 pm EDT
Registration: https://zoom.us/meeting/register/tJ0lfuGpqjsiH9P5Z1fZQBJHT9V-H0lFnwZR
Presentation Title: Optimization of Vero-cell manufacturing of deltaFLU universal influenza vaccine
Authors: Amy Aspelund, Melissa Vivian, Alaura Hoag, Markus Wolschek, Manfred Reiter, Boris Ferko and Thomas Muster
About Vivaldi Biosciences
Vivaldi Biosciences is developing its DeltaFLU universal influenza vaccine to provide broad protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. Administered as a nasal spray, DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1 (NS1). The NS1 protein blocks interferon, a key component of the immune system’s response to viral infection. Lacking NS1, DeltaFLU rapidly induces interferon and broadly neutralizing mucosal antibodies in the nasal passages, creating a first line of defense directly at the point of entry of circulating viruses. The self-adjuvanting effect of interferon also creates a second line of defense by stimulating the immune system’s T cells and antibody-producing B cells to achieve a broadly protective systemic immune response. DeltaFLU strains are replication-deficient and are not shed by the recipient, providing significant safety advantages. Four completed clinical studies show DeltaFLU is safe and generates a potent, broad immune response. Nonclinical studies demonstrate the feasibility of universal protection with DeltaFLU, showing protection against challenge with drifted and shifted influenza A and B strains. Vivaldi has established a high-yield Vero cell production system enabling efficient, low-cost production of DeltaFLU. The 7-week production timeline enables rapid response to an influenza pandemic. Vivaldi Biosciences is based at the Research Innovation Center at Colorado State University, Fort Collins, CO and in Vienna, Austria. NGN Capital LLC is the lead investor in Vivaldi Biosciences. Additional information can be found at www.vivaldibiosciences.com.